Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/9332
Title: Reconstructing the skeleton with intermittent parathyroid hormone.
Austin Authors: Seeman, Ego ;Delmas, Pierre D
Affiliation: Austin and Repatriation Medical Centre, University of Melbourne, Victoria, Australia
Issue Date: 1-Sep-2001
Publication information: Trends in Endocrinology and Metabolism: Tem; 12(7): 281-3
Abstract: The aim of treating osteoporosis is to restore bone strength by increasing its mass and reconstructing its architecture. Antiresorptive drugs reduce bone remodeling, allowing more complete secondary mineralization of the existing bone; the mass, macro- and microarchitecture of the bone remains unchanged. Anabolic agents have the potential to achieve this goal. Parathyroid hormone (PTH) is famous for its catabolic actions. Its anabolic effects, known by a select few over 70 years ago, are finally being appreciated. There is widely reproduced and compelling evidence in a range of species made osteoporotic by gonadectomy that intermittent PTH administration restores bone strength by stimulating new bone formation on the periosteal (outer) and endosteal (inner) bone surfaces, enlarging bone diameter, thickening the cortices and existing trabeculae, and perhaps increasing trabecular numbers and their connectivity.
Gov't Doc #: 11504661
URI: http://ahro.austin.org.au/austinjspui/handle/1/9332
URL: https://pubmed.ncbi.nlm.nih.gov/11504661
Type: Journal Article
Subjects: Animals
Bone Resorption.prevention & control
Bone and Bones.injuries
Female
Fractures, Bone.prevention & control
Humans
Osteoporosis.drug therapy
Osteoporosis, Postmenopausal.drug therapy
Parathyroid Hormone.administration & dosage.therapeutic use
Randomized Controlled Trials as Topic
Appears in Collections:Journal articles

Show full item record

Page view(s)

8
checked on Dec 1, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.